The Bioabsorbables/Bioresorbables Center

Filter Your Results

 

News

 

A Novel, Radiopaque, Bioresorbable Tyrosine-Derived Polymer for Cardiovascular Scaffolds

Gregor Leibundgut, MD

July/August 2018—The REVA Medical Fantom bioresorbable scaffold is available under CE Mark only and is not approved in the United States. First-generation, drug-eluting, bioresorbable c…

Expanding the Possibilities of PCI

Ted E. Feldman, MD, MSCAI, FACC, FESC

May/June 2018— Now that percutaneous coronary intervention (PCI) has become an established therapeutic option in multiple patient populations, we find ourselves in a position to improve …

Ask the Experts: Will Bioresorbable Scaffolds Ultimately Have a Role?

With Dean J. Kereiakes, MD, FACC, FSCAI; Ron Waksman, MD, FACC, FSCAI, FESC; James B. Hermiller Jr, MD, FACC, MSCAI; and Jarrod D. Frizzell, MD, FACC, SCAI

May/June 2018—Experts discuss the outcomes of the ABSORB trials and what the future may hold for bioresorbable scaffolds.

Implantation Technique for Bioresorbable Scaffolds

Jiang Ming Fam, MD, MBBS; and Robert-Jan van Geuns, MD

January/February 2017—Device description and patient/lesion selection with the Absorb BVS.

Bioresorbables Plus Access & Closure

Ted E. Feldman, MD, MSCAI, FACC, FESC

May/June 2016— In this issue we highlight bioresorbable stent technologies and vascular access and closure. There are reviews covering recent trial results and the details of bioresorbab…

Current Status of Trial Outcomes for the Absorb Stent

Salvatore Cassese, MD, PhD

May/June 2016—How does Absorb compare to everolimus-eluting metallic stents?

Understanding the Technical Aspects of Bioresorbable Stent Implantation

Ashok Seth, FRCP, FACC, FSCAI, FESC, FCSI, DSc, DLitt; Vijay Kumar, MD, DNB; and Babu Ezhumalai, MD, DM, FNB, FISE

May/June 2016—The new Absorb polymer-based scaffold requires optimal implantation technique for best results.

How Will New Bioresorbable Polymer Drug-Eluting Stents Impact DAPT Duration?

Ian J. Sarembock, MBChB, MD, FACC; and Dean J. Kereiakes, MD, FACC

May/June 2016—Current bioresorbable polymer, everolimus-eluting stent technology appears well suited for abbreviated-duration dual-antiplatelet therapy.

 

advertisement

Top 5 Top 5 In Bioabsorbables/Bioresorbables Center

FDA Seeks to Strengthen Public Warnings and Recall Notifications; CDRH Outlines Strategic Priorities

Lepu Medical's NeoVas Bioresorbable Scaffold Shown to Be Noninferior to Metallic Drug-Eluting Stents

Five-Year DESSOLVE Data Published for Micell's MiStent

BIORESOLVE-ISR Study Compares Use of BVS With DCB and EES for Coronary ISR

Reva Medical's 2.5-mm Fantom Encore Bioresorbable Scaffold Receives CE Mark Approval

 

Centers

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

Other Resources

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.